Olaparib

Olaparib is a prescription medication that belongs to a class of drugs known as poly (ADP-ribose) polymerase (PARP) inhibitors. It is primarily used to treat certain types of cancer, including ovarian, breast, and prostate cancers. Olaparib works by inhibiting the PARP enzyme, which is involved in repairing damaged DNA within cancer cells. By blocking this enzyme, the medication prevents cancer cells from repairing their DNA, leading to cell death and ultimately, a reduction in tumor size.
Olaparib is often prescribed for patients with advanced cancers that have a specific genetic mutation, such as BRCA1 or BRCA2. This medication is typically used in combination with other cancer treatments, including chemotherapy and targeted therapies, to improve overall treatment outcomes.
Olaparib may cause side effects, such as nausea, vomiting, fatigue, and anemia. Patients should discuss these potential side effects with their healthcare provider to determine the most appropriate treatment plan. Additionally, olaparib should not be used by individuals who are pregnant or breastfeeding, as it may harm the developing fetus or baby.